Andecaliximab
mAbexperimental
Clinical trial activity
15 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Mar 1, 2013 (NCT01831427)
Timeline
Indications
Studied for
- Arthritis, Rheumatoid · Phase 2
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Colitis, Ulcerative · Phase 2/Phase 3
- Colorectal Neoplasms · Phase 1
- Crohn Disease · Phase 2
- Cystic Fibrosis · Phase 2
- Esophageal Neoplasms · Phase 2
- Glioblastoma · Phase 1
- Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1
- Pulmonary Disease, Chronic Obstructive · Phase 1
- Stomach Neoplasms · Phase 3
Mechanism of action
- Matrix metalloproteinase 9INHIBITOR
MMP9 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3833374 ↗
Also known as
- andecaliximab
- gs-5745
- gs-5745
- gs-5745
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06274437 | Phase 1 | Jun 2, 2024 | Biond Biologics |
| NCT06840119 | Phase 1/Phase 2 (Phase 2) | Jan 10, 2024 | Immunocore Ltd |
| NCT03631836 | Phase 1 | Jan 1, 2019 | Aix-University of Marseille |
| NCT02862574 | Phase 2 | Dec 15, 2016 | Gilead Sciences |
| NCT02759562 | Phase 2 | Nov 4, 2016 | Gilead Sciences |
| NCT02862535 | Phase 1 | Sep 20, 2016 | Gilead Sciences |
| NCT02864381 | Phase 2 | Sep 1, 2016 | Gilead Sciences |
| NCT02545504 | Phase 3 | Oct 13, 2015 | Gilead Sciences |
| NCT02520284 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2015 | Gilead Sciences |
| NCT02405442 | Phase 2 | Apr 1, 2015 | Gilead Sciences |
| NCT02209987 | Phase 1 | Aug 1, 2014 | Gilead Sciences |
| NCT02176876 | Phase 1 | Aug 1, 2014 | Gilead Sciences |
| NCT02077465 | Phase 1 | Mar 1, 2014 | Gilead Sciences |
| NCT01803282 | Phase 1 | Mar 29, 2013 | Gilead Sciences |
| NCT01831427 | Phase 1 | Mar 1, 2013 | Gilead Sciences |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 12 | 12 | 3 | 2013 |
| Aix-University of Marseille | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Biond Biologics | For profit | 1 | 1 | 1 | 2024 |
| Immunocore Ltd | For profit | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1